Doctors review records to check RSV prevention Drug's Real-World impact
NCT ID NCT07485907
Summary
This study aims to understand how well the RSV prevention medication nirsevimab works in real-world settings. Researchers will look back at the medical records of 1,000 infants under 1 year old who were hospitalized for bronchiolitis. They will compare hospitalization rates between infants who received the preventive drug and those who did not.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ACTIV
Créteil, 94000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.